US Insurers Lash Out At Specialty Drug Manufacturer over High Price

May 20, 2014 11:48 PM

12 0

The war on the ever climbing U.S healthcare costs rages on, and the latest attack came from the U.S health insurance trade group AHIP. The group lashed out at Gilead, who just recently launched their all oral Hepatitis C treatment Sovaldi which is priced at $84,000.

The America’s Health Insurance Plans, accused pharmaceutical companies of unsustainable pricing of their specialty medications and taking advantage of the insurance system. While commanding Sovaldi on its success and innovation, AHIP also says that the drug price is unsustainable. There is no price ...

Read more

To category page